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ORIGINAL ARTICLE
INTRODUCTION
In 1971, specific amino acid treatment came into
therapeutic arena for liver cirrhosis patients, i.e. when
Fischer and Baldessarini first introduced the associa-
tion between hepatic encephalopathy an imbalance of
plasma amino acid through false neurotransmitter
synthesis.1,2 Since that time, many studies, both
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ABSTRACT
Background: This study was also conducted to determine the effects of high-branched chain amino
acid (BCAA) enteral supplementation on altered nutritional status parameters (including plasma prealbumin)
and hepatic encephalopathy parameters in liver cirrhosis patients with hepatic encephalopathy.
Method: Our study was a randomized, single-blinded experimental study comparing between control
group of liver cirrhosis patients with standard hospital liver diet (40 kcal/kgBW/day for male and
35 kcal/kgBW/day for female; protein 1.25 g/kgBW/day) and experimental group of liver cirrhosis
patients with liver diet modification high in BCAA supplementation, which had similar protein and calorie
calculation as the control group.
Results: Subclinical hepatic encephalopathy prevalence was 32%. In the experimental group, prealbumin
plasma, arm circumference, body weight and body mass index (BMI) increased; whereas in the control
group, prealbumin plasma, arm circumference, body weight and BMI decreased (p < 0.05).
In experimental group, the ammonia level significantly decreased (p < 0.01). Clinical hepatic encephalo-
pathy, flapping tremor, the number connection test (NCT) did not show significant changes between the
two groups. However, there was worsening trend in the control group. Level of albumin, bilirubin, AST,
ALT did not show any significant difference between both groups.
Conclusion: High-BCAA enteral supplementation which is administered to liver cirrhosis patients with
hepatic encephalopathy for 14 days could improve plasma prealbumin level, arm circumference, body
weight, BMI and could decrease the plasma ammonia level. However, it does not improve Fischer ratio,
psychometric test and electroencephalography
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clinically and experimentally, had been conducted  to
confirm their hypothesis, as well as an effort to
improve mental status through amino acid
supplementation. However, after three decades pass
by, the problem remains unsolved. Nevertheless, a lot
of information has been collected related to
metabolism of energy, amino acids and protein in liver
cirrhosis patients.
Hepatic encephalopathy (HE) is a neuro-
psychiatric syndrome that only occur in a significant
liver dysfunction condition. It can be caused by
various clinical conditions such as congenitally urea
cycle disorders, acute or chronic liver diseases,
spontaneous/iatrogenic portosystemic venous shunting,
including after the placement of transjugular
intrahepatic portosystemic shunt (TIPS).1,2
HE may occur in 50-70% of liver cirrhosis patients,
including the abnormality than can only be assessed by
psychometric test.2 Data based on hospital care unit
reveals that there was 1.34-14.5% of patients with liver
disease, and 20-73.8% of them had liver cirrhosis.3
Clinical manifestation of hepatic encephalopathy
varied from imperceptible clinical symptoms (e.g.
subclinical hepatic encephalopathy, that can only be
detected by psychometric test) to deep coma.
Subclinical hepatic encephalopathy identified by
electrophysiologic abnormalities and psychometric test.
Since the level of consciousness is not disturbed, it is
difficult to assess the clinical impact of subclinical
hepatic encephalopathy. However, a clinical relation
had been reported with respect to decreased ability of
driving and deterioration in quality of life.1
An important factor explaining the pathogenesis of
hepatic encephalopathy is the role of branched-chain
amino acid (BCAA) ratio or aromatic amino acids
(AAA) ratio. Some studies that evaluate benefit of
BCAA therapy in liver cirrhosis patients and hepatic
encephalopathy give varied results.2-17 In general,
BCAA has protein sparing effect.6,13 BCAA effect on
hepatic encephalopathy has to be clarified.
Prealbumin is one of indicators for nutritional
status. The half-life of prealbumin metabolism is
1-2 days, and half-life of albumin and transferrin are
longer (7-21 days); while, the half-life of retinol
binding protein is very short (10 hours).18-20  Foreign
literatures demonstrate that studies concerning on the
effects of BCAA supplementation are especially
related to alcoholic liver-cirrhosis patients. In contrast,
only few studies in non-alcoholic liver cirrhosis has been
reported. This study was done to determine
the effects of high enteral BCAA supplementation on
altered nutritional status parameters (including
plasma prealbumin) and hepatic encephalopathy
parameters.
METHOD
This study was conducted on February 1998 till
August 2000 at Division of Hepatology, Department
of Internal Medicine, Cipto Mangunkusumo hospital.
It was a randomized, single-blinded experimental study
comparing between control group of liver cirrhosis
patients with standard hospital liver diet (40 kcal/kgBW/
day for male and 35 kcal/kgBW/day for female;
protein 1.25 g/kgBW/day) and experimental group of
liver cirrhosis patients with liver diet modification high
in BCAA supplementation, which had similar protein
and calorie calculation as the control group. Such
method was utilized to determine the effects of high-
BCAA enteral supplementation on altered nutritional
status parameters (including plasma prealbumin) and
hepatic encephalopathy parameters.
Method: randomized, controlled
Experimental group nutrisi enteral AARC
n = 17
!
Control group diet standar
n = 17
!
n = 34
Hospitalized  Home visit
Initial examination    Final/end examination
0 7 14
Figure 1. Method illustration of this randomizedcontrolled clinical trial
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RESULTS
Thirty-four eligible liver cirrhosis patients were
included (17 patients in the control group and
17 patients in the experimental group) in this
study (table 1).
 There were no significant difference in
charac-teristics of both groups according to age
distribution, gender, Child-Pugh classification, level of
education and viral etiology. Results of clinical data,
psychometric test, initial and end of electroen-
cephalography (EEG) in both groups were showed on
table 2 and 3.
Tabel 1. Patient characteristics in both groups 
Experimental Control Characteristic 
n (%) n (%) p 
Gender   > 0.05π 
Male 11 (64.7) 10 (58.8)  
Female 6 (35.3) 7 (41.2)  
Education   > 0.05π 
Uneducated 1 (5.9)   
Elementary school 3 (17.65) 4 (23.5)  
Secondary school 3 (17.65) 1 (5.9)  
Tertiary school 5 (29.4) 8 (47.1)  
College 5 (29.4) 4 (23.5)  
Child Pugh   > 0.05π 
A 8 (47.1) 10 (58.8)  
B 5 (29.4) 6 (35.3)  
C 4 (23.5) 1 (5.9)  
Viral etiology   > 0.05π 
Non B non C 3 (17.65) 2 (11.8)  
B 3 (17.65) 4 (23.5)  
C 11 (64.7) 9 (52.9)  
B & C  2 (11.8)  
Age (year)   > 0.05τ 
 Mean ± SD 56.24 ± 8.29 56.82 ± 7.27  
Note: π = Pearson chi-square test; τ = t-test for independent samples;  
SD = standard deviation 
Table 2. Clinical data, psychometric test and initial and end of EEG in both groups 
 Experimental Control 
 Initial n (%) End n (%) Initial n (%) End n (%) 
Hepatic encephalopathy     
   None 3 (17.6) 5 (29.4) 8 (47.1) 7 (41.2) 
   Grade I 12 (70.6) 12 (70.6) 8 (47.1) 9 (53) 
   Grade II    2 (11.8) 0 1 (5.8) 1 (5.8) 
Flapping tremor         
   None 12 (70.6) 13 (76.5) 11 (64.7) 9 (53) 
   Grade I 5 (29.4) 4 (23.5) 6 (35.3) 7 (41.2) 
   Grade II 0 0 0 1 (5.8) 
Number connection test (second)    
   Grade I = 31-50 4 (23.5) 7 (41.2) 5 (29.4) 7 (41.2) 
   Grade II = 51-80 10 (58.9) 7 (41.2) 6 (35.3) 6 (35.3) 
   Grade III = 81-120 2 (11.7) 2 (11.7) 5 (29.4) 3 (17.6) 
   Grade IV ? 120 1 (5.9) 1 (5.9) 1 (5.9) 1 (5.9) 
Ammonia (nmol/L)     
   Normal ? 45 2 (11.8) 7 (41.2) 6 (35.3) 7 (41.2) 
   Grade 1= 45 - 60 5 (29.3) 2 (11.8) 4 (23.5) 7 (41.2) 
   Grade 2 = 61 - 75 1 (5.9) 3 (17.6) 4 (23.5) 0 
   Grade 3 = 76 - 90 2 (11.8) 2 (11.8) 1 (5.9) 0 
   Grade 4 > 90 7 (41.2) 3 (17.6) 2 (11.8) 3 (17.6) 
Ascites     
   None 13  15 12 17 
   Mild 2 2 5 0 
   Moderate 2 0 0 0 
EEG     
   Normal 12 (70.6) 13 (76.5) 13 (76.5) 14 (82.4) 
   Grade  2 5 (29.4) 4 (23.5) 4 (23.5) 3 (17.6) 
Note: Initial = before experimental study proceed (beginning); End = after experimental study was done 
for 14 days (end of study); EEG: Electroencephalography 
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Table 3. Laboratory and psychometric test results at the beginning and end of study in both groups  
Experimental Control 
Parameter Initial End Initial End ρτ 
χ ± SD χ ± SD χ ± SD χ ± SD 
Arm circumference (cm) 
Body weight (kg) 
Body mass index 
Number connection test 
(second) 
AST (U/L) 
ALT (U/L) 
Total bilirubin (mg/dL) 
Direct bilirubin (mg/dL) 
Albumin (g/dL) 
Globulin (g/dL) 
Prealbumin (g/L) 
Plasma ammonia (nmol/L) 
Fischer ratio (χ/Μ/κ) 
20.06 ± 11.62 20.12 ± 11.66 
55.68 ± 7.13 56.21 ± 6.91 
21.80 ± 3.13 22.02 ± 3.18 
69.29 ± 29.59 64.41 ± 35.77 
45.12 ± 25.37 41.53 ± 34.32 
29.71 ± 17.56 25.94 ± 16.82 
1.53 ± 1.49 1.12 ± 0.93 
0.84 ± 0.88 0.59 ± 0.56 
3.32 ± 1.09 3.24 ± 1.12 
3.34 ± 1.07 3.27 ± 1.12 
0.11 ± 0.049 0.12 ± 0.054 
88.41 ± 50.04 * 64.47 ± 37.39 * 
3.36/1.97/ 3.87/1.54/ 
0.42-20.45 0.23-16.73 
24.85 ± 9.97 24.75 ± 9.96 0.035 
58.76 ± 12.87 58 ± 12.71 0.041 
23.50 ± 4.51 23.14 ± 4.26 0.031 
71.41 ± 27.17 67.18 ± 27.56 0.921 
36.41 ± 35.57 35.53 ± 33.12 0.775 
24.41 ± 17.75 25.12 ± 26.04 0.486 
1.05 ± 0.63 0.92 ± 0.5 0.320 
0.48 ± 0.35 0.49 ± 0.38 0.064 
3.35 ± 1.16 3.23 ± 0.93 0.905 
3.39 ± 1.62 3.24 ± 1.15 0.782 
0.14 ± 0.079 0.14 ± 0.063 0.016 
71.24 ± 51.26 55.29 ± 24.97 0.577 
2.31/1.97/ 2.69/1.84/ 
0.951 
0.40-9.28 0.16-11.11  
Note: Initial: before experimental study proceed (beginning); end: after study was done for 14 days (end of study); 
SD: standard deviation; Μ: median; κ: range minimum-maximum: mean; τ: t-test for independent samples; (*): t test for 
pair group p < 0.01 
 
Grade of Clinical Hepatic Encephalopathy 
Statistic test of Pearson Chi-square showed 
significant difference between both groups (p = 0.033). 
On the contrary, the Fisher’s exact test did not show 
significant difference between both groups (p = 0.103). 
 
 
 
 
 
 
 
 
 
 
 
Flapping Tremor 
In the experimental group, no worsening grading of 
flapping tremor was found. However, in the control 
group, there were five patients got worse condition. 
Psychometric Test/Number Connection Test 
In both experimental and control groups, there were 
no patient had number connection test (NCT) grade 0. 
Thus, our study found hepatic encephalopathy in all 
patients with liver cirrhosis. Statistic test with Pearson 
Chi-square (p = 0.067) and Fisher’s exact (p = 0.141) 
did not show any significant difference between both 
groups. 
 
Table 6. Altered grading of NCT in both groups 
Worsen/no change Improved 
Experimental 3 14 
Control 8 9 
Note: Pearson Chi-square test p = 0.067; RRR = 0.63; ARR = 0.29; 
Fisher’s exact test p = 0.141; NNT = 3.4; CI 95% 
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Electroencephalography 
Statistic test between both groups showed no 
significant difference. 
Table 7. Altered grading of EEG in both groups 
No change Improved 
Experimental 16 1 
Control 16 1 
Note: Pearson Chi-square test, p = 1.00; Fisher’s exact test p 
= 1.00 
DISCUSSION 
Liver is the main organ in metabolism of carbo- 
hydrate, fat, protein, vitamin, mineral and trace  
element. Liver has important role in protein and amino  
acids metabolism. Liver processing amino acids that  
derived from diet or released by skeletal muscles due  
to protein degradation (catabolism). Liver uses amino  
acids, particularly for the need of protein synthesis and  
gluconeogenesis. Liver also regulates amino acids  
supply for peripheral tissues and changes excessive  
amino acids into urea. Therefore, in patient with liver  
cirrhosis, the capability to regulate amino acids, both in  
plasma as well as tissues could be very disturbed.13,14,15  
 In the early 1980’s, it was postulated that hepatic  
encephalopathy in liver cirrhosis could be improved by  
giving formulation of protein enriched by BCAA with  
just few of AAA (phenylalanine, tyrosine, tryptophan).  
Such opinion is supported by the results of observation  
on plasma amino acids profile in liver cirrhosis patients,  
which is characterized by accumulation of AAA and  
decreased level of gluconeogenic amino acids,  
especially BCAA. It is well known that BCAA - 
leucine, isoleucine and valine - are unique amino acids  
due to their extra hepatic metabolism in skeletal  
muscles. In muscles, BCAA is available as important  
energy substrates for exercise, stress period and as  
precursor of others amino acids synthesis and  
protein. 
59  
 
Table 4. Altered grading of hepatic encephalopathy in both 
groups 
 Worsen/no change Improved 
Experimental 13 4 
Control 17 0 
Note: Pearson Chi-square test p = 0.033; RRR = 0.24; ARR = 0.24  
Fisher’s exact test p = 0.103; NNT = 4; CI 95% 
Table 5. Altered grading of flapping tremor in both groups 
 Worsen/no change improved 
Experimental  16 1 
Control 15 2 
Note: Pearson Chi-square test, p = 0.545; Fisher’s exact test 
p = 1.00 
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Early studies of BCAA were commonly focused
on the anabolic effects, especially in conditions of
catabolic stress disorders and theoretically potential to
prevent or treat encephalopathy in liver failure.
Therefore, BCAA was promoted as beneficial
supplementation in these patients. However, some
similar clinical studies seem to cause decreased
interest in nutritional supplementation of BCAA.13,16,17
Considering that BCAA is a protein precursor, so
becoming a paradox if evaluation of liver disease has
only been focused on the effects of mental function
and ignoring evaluation of their nutritional effects with
only a few studies about therapeutic effects of BCAA
on the energy balance which were conducted in the
years 1980’s  to early 1990’s.17
The main rationalization on BCAA utilization in
hepatic encephalopathy patients has becoming wane
since its first promotion in 1975. It has shifting to and
focusing on their nutritional effects, for example in
improving malnutrition, which is common finding in liver
cirrhosis patients that greatly determine the prognosis.
Potential benefit of leucine, valine and isoleucine in liver
cirrhosis patients with malnutrition is an independent
effect. It does not depend on therapeutic value of
hepatic encephalopathy. BCAA inhibits protein
catabolism in muscles. BCAA also increases the
synthesis of muscle and liver protein and also available
as sources of energy substrates for muscle tissues.
In this study, we evaluate the therapeutic effects of
BCAA supplementation on nutritional status, which was
represented by plasma prealbumin level and effect of
BCAA supplementation to encephalopathy hepatic
parameters. Since the half-life of prealbumin
metabolism is 1-2 days,  prealbumin is regarding to be
appropriate for the study; not to mention considering
the half-life of albumin and transferrin are too long
(7-21 days) or the half-life of retinol-binding protein is
too short (10 hours).18,19,20
Our study found significant difference in nutritional
status parameter between the experimental and
control groups. There was increased plasma
prealbumin level correlated to increased arm circum-
ferences, body weight, and BMI in the experimental
group. However, the control group demonstrated
decreased plasma prealbumin level, arm circumference,
body weight or BMI. Such findings supports the facts
that the most consistent findings related to BCAA
is protein-spare of BCAA in liver cirrhosis
patients.11,13,21-28 Arm circumference is a more accu-
rate parameter in liver cirrhosis patients compared to
body weight or BMI, since ascitic fluid does not
accumulate in arm circumference. If we measure
the triceps skinfold thickness (TST), then by using
Bishop formula, we will get the arm muscle
circumference (AMC). Both TST and AMC are also
accurate anthropometric parameters in liver cirrhosis
patients, that can be measured by this calculation:
AMC (cm) = AC (cm) – 0.314 x TSF (mm).11
We found 11 patients with clinically normal hepatic
encephalopathy/grade 0; while  the results of psycho-
metry test revealed no one as normal on NCT, so there
were 32% of patients with sub-clinical hepatic
encephalopathy. In the literatures, the prevalence of
hepatic encephalopathy is around 20–84%.29-31
Several studies found significant improvement of
clinical hepatic encephalopathy after supplementation
of high BCAA diet.5,7,32,33 However, some others
studies and a metaanalysis study did not found benefit
of BCAA supplementation in hepatic encephalopathy
nor improved mortality rate of hepatic encephalopathy
patients.11,34,35 In this study, we found no significant
improvement of hepatic encephalopathy. However,
data’s showed that there is a trend of improvement in
the experimental group compare to the control group
which have worsening trend. In the experimental group,
four patients had improvement in clinical hepatic
encephalopathy grading and no one got deteriorate.
Meanwhile, in the control group, there is no one got
improvement and one patient got worsening condition.
Psychometric test is a tool to assess the presence
of neuropsychiatry disturbances in liver cirrhosis
patients. Several studies showed that BCAA
supplementation could improve psychometric test
significantly.9,32,33 However, it was known that result
of psychometric test is very much influenced by
certain factors including learning/training effect,
educational status, mind perception, intellectuality, level
of intelligent, the need for age-matched controls, etc.30,36
In this study, there is no significant difference
between both groups. However, there were more
patients (14 patients) who had improved NCT in
the experimental group compared to the control group
(9 patients), and there were more patients (7 patients),
who got worsen NCT in the control group compared
to the experimental group (3 patients).
Flapping tremor is also one of hepatic encepha
lopathy signs. As well as NCT, in this study, there is no
significant difference between both groups. However,
in the control group, we found 5 patients with
deterioration; while in the experimental group, there
were no one got deteriorated. Such finding is different
from other studies that found significant improvement
in flapping tremor grading with high-BCAA supplemen-
tation
EEG is considered could give more objective result
than psychometric test in assessing hepatic
encephalopathy since it does not depend on age and
educational status and does not show learning effect
on repeated examination. However, its diagnostic
sensitivity is lower than psychometric test.29,36 Some
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of EEG limitations are insensitive in deep brain
activity, changes related to age and change in
conditions such as level of alertness or drowsiness and
individual different variabilities.37 In this study, there is
no significant difference on EEG changes between the
control and experimental groups. Higuchi et al  found
a significant prolonged latent P3 wave by evoked
potential examination in liver cirrhosis patients
compared to control group.33
Metabolism disturbance in liver cirrhosis could
decrease Fischer ratio. In this study,  Fisher ratio mostly
less than 3 (70%) with values range of 0.1606–20.4509.
Supplementation of high-BCAA diet could improve
Fisher ratio significantly.6,38 This study does not
demonstrate significant increase of Fisher ratio between
the experimental and control groups, although there is
increased Fisher ratio in both groups. Variation of Fisher
ratio values could occur since the amino-acids turn over
is very dynamic. Thus, the high or low plasma amino
acids level does not always reflect the utilization of
such amino acids. Besides that, there were other
factors influencing contents of amino acids in plasma,
such as duration of fasting, variability of timing to get
blood samples or patient metabolism status. Kinetic
studies is more appropriate in reflecting amino acids
utilization.21,39
Effects of supplementation of high-BCAA diet on
plasma ammonia level  is various. Several studies
showed decreased plasma ammonia level after giving
high-BCAA diet due to increased clearance of blood
ammonia.33,40 In this study, we found decreased
plasma ammonia level, both in the experimental and
control groups. Although there is no significant
difference between both groups; however, decreased
plasma ammonia level in the experimental groups
before and after treatment showed significant
difference.
Our study also demonstrates no significant
differences between both groups regarding changes in
level of albumin, globulin, AST and ALT. In this study,
even there is no significant difference between both
groups and no significant difference amongst each
group, but albumin level in both groups decreased. Such
phenomenon is a more reflecting condition of
pre-study considering the half-life of albumin is very
long (21 days) due to large albumin pool size.
Therefore, the fluctuation of albumin turnover will not
immediately reflected in plasma albumin level.
Albumin is not a sensitive indicator for nutritional
status parameter, particularly to assess alteration in
short-time period.
In this study, nutritional status parameters provided
more significant result compared to hepatic
encephalopathy parameters. However, hepatic
encephalopathy parameters showed a tendency of
improvement in the experimental group. This could be
occurred considering that factors influencing hepatic
encephalopathy parameters are more variable and it is
affected not only by  protein/BCAA supplementation.
These will influence the study results, considering that
patients in this study are mostly ambulatory.
Although the effort of nutritional supervision has
been conducted strictly enough; however, control on
others factors that can influence to hepatic encepha-
lopathy are hardly enough to be done, e.g. different
defecation habit pattern among patients, the occurrence
and absence of constipation, antibiotic consumption at
home, laxative consumption, the presence of occult
bleeding, electrolytes disturbances, etc. In future
studies, all patients should be hospitalized and
strictly monitored, so that the BCAA supplementation
will be the only factor to be assessed that affect
both experimental and control groups. In addition,
to observe better results in hepatic encephalopathy
parameters, the treatment  should be proceed in
longer duration than this study (14 days) and with
 larger samples.
BCAA supplementation provides benefit and it could
be well-tolerated by almost all patients, there was only
1 patients suffering diarrhea and could not complete
the study. Limitation in utilizing BCAA supplementa-
tion right now in liver cirrhosis patients is
the expensive cost.
Branched-chain amino acids (BCAA), i.e. leucine,
isoleucine and valine are essential amino acids that
cannot be produced by the body. In fact, it must be
obtained from diet, and primarily metabolized by muscle
mass rather than by liver. The use of BCAA remains
controversial and they are not widely available in many
centers due to their expense and unpalatability. The
European Society on Parenteral and Enteral Nutrition
Guidelines recommends that enteral feed enriched with
BCAA should be reserved for patients who develop
encephalopathy with enteral feeding despite
appropriate treatment. This represents a very small
proportion of patients.41,42,43,44
CONCLUSION
High-BCAA enteral nutrition supplementation for
14 days may increase plasma prealbumin level, arm
circumference, body weight, body mass index and may
decrease plasma ammonia level in liver cirrhosis
patients. BCAA enteral supplementation could not
provide significant improvement of Fischer ratio,
 psychometric test, and electroencephalography for liver
cirrhosis patients in this study. The prevalence of
subclinical hepatic encephalopathy in this study is 32%.
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